Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2019-09-08
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare pazopanib to temsirolimus in the
treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be
studied.
Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for
tumor growth. This may prevent or slow the growth of cancer cells.
Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells to
die.
This is an investigational study. Pazopanib and temsirolimus are both FDA approved and
commercially available for the treatment of kidney cancer. It is investigational to compare
the 2 drugs.
Up to 90 patients will be enrolled in this study. All will be enrolled at MD Anderson.